Publication Name	World Journal of Stem Cells
Manuscript ID	15392
Country	Italy

Received	2014-11-25 08:43
Peer-Review Started	2014-11-26 19:10
To Make the First Decision	2015-01-08 14:02
Return for Revision	2015-01-14 11:11
Revised	2015-01-27 01:40
Second Decision	2015-07-06 08:31
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-07-17 14:24
Articles in Press	2015-07-17 14:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-15 21:52
Publish the Manuscript Online	2015-08-27 10:51

ISSN	1948-0210 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Advancement in high dose therapy and autologous stem cell rescue in lymphoma
Manuscript Source	Invited Manuscript
All Author List	Alessandro Isidori, Cristina Clissa, Federica Loscocco, Barbara Guiducci, Sara Barulli, Lara Malerba, Elisa Gabucci and Giuseppe Visani
Funding Agency and Grant Number
Corresponding Author	Alessandro Isidori, MD, PhD, Haema­tology and Haematopoietic Stem Cell Transplant Center, Marche Nord Hospital, Via Lombroso, 61100 Pesaro, Italy. asidori@gmail.com
Key Words	Hodgkin lymphoma; Non-Hodgkin lym­phoma; High dose therapy; Autologous stem cell transplantation; New drugs
Core Tip	High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is consi-dered the golden standard for the vast majority of patients with both Hodgkin and non-Hodgkin lym-phoma, who either relapse or never attain a remis-sion. However, several questions about HDT/ASCT still remain unanswered, also comprising, but not limited to, its role in newly diagnosed patients with advanced stage disease. The incorporation of novel drugs in both salvage and conditioning regimens has recently revitalized the HDT/ASCT area, with several phase I-II trials performed during the last 5 years. This review will focus on the most recent data regarding HDT/ASCT in lymphomas.
Publish Date	2015-08-27 10:51
Citation	Isidori A, Clissa C, Loscocco F, Guiducci B, Barulli S, Malerba L, Gabucci E, Visani G. Advancement in high dose therapy and autologous stem cell rescue in lymphoma. World J Stem Cells 2015; 7(7): 1039-1046
URL	http://www.wjgnet.com/1948-0210/full/v7/i7/1039.htm
DOI	http://dx.doi.org/10.4252/wjsc.v7.i7.1039

Full Article (PDF)	WJSC-7-1039.pdf
Full Article (Word)	WJSC-7-1039.doc
Manuscript File	15392-Review.doc
Answering Reviewers	15392-Answering reviewers.pdf
Audio Core Tip	15392-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	15392-Conflict-of-interest statement.pdf
Copyright License Agreement	15392-Copyright assignment.pdf
Peer-review Report	15392-Peer-review(s).pdf
Scientific Misconduct Check	15392-Scientific misconduct check.pdf
Scientific Editor Work List	15392-Scientific editor work list.pdf